Julian Baker, an insider at Kymera Therapeutics Inc (KYMR), purchased 701,326 shares of the biotechnology company on December 10, 2025, at a price of $86.00 per share. This transaction amounts to a total value of $60.31 million. Following this purchase, Baker holds the same number of shares in the company.
Kymera Therapeutics, based in Watertown, Massachusetts, specializes in developing small molecule therapeutics that degrade disease-causing proteins. The firm focuses on immunology and is currently advancing its lead programs, including KT-621, which is in a Phase I clinical trial, and KT-579, an investigational oral degrader of IRF5.
As of November 20, 2025, Kymera Therapeutics has a market capitalization of $4.7 billion and an EPS of -3.59. The company is expected to report earnings on May 7, 2026, with an estimated EPS of -0.99 and revenue of $10.2 million.
Insider transactions provide transparency into executive sentiment regarding company performance. While Baker's purchase may suggest confidence in Kymera's future, investors should consider multiple insider activities and broader market factors before making decisions.